MYCOBUTIN
What it isRNA-polymerase-inhibiting rifamycin; mycobacterial prophylaxis and treatment in people with HIV.
Why this oneMuch weaker enzyme induction than rifampin permits combinations with some antiretrovirals that rifampin disrupts.
What limits itUveitis and neutropenia require attention; interactions remain bidirectional, and body fluids turn orange.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Disseminated MAC prophylaxis (advanced HIV) | adult | 300 mg QD | 300 mg QD | 300 mg QD |
Renal Mild-moderate: no adjustment; CrCl <30: consider 50% dose reduction if toxicity suspected
Hepatic Mild: no adjustment; moderate-severe: not studied
Pregnancy Use only if potential benefit justifies risk; animal fetal effects (decreased viability, skeletal variants)
Lactation Undefined
NO BOXED WARNINGS
Principal riskUveitis and neutropenia
Cost, est. cash$10–$300/month
Generic entry2014
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
